Prolyl hydroxylase domain 3 (PHD3), a rate-limiting enzyme regulating HIF-1α degradation, improves radiotherapy efficacy through inhibiting p-EGFR/HIF-1α signaling in pancreatic cancer [92]. Here, HIF1A is linked to pancreatic neoplasm.